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ELMOD2 Is a Candidate Gene for Familial Idiopathic Pulmonary
Fibrosis
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Vesa Ollikainen, Kaisa Salmenkivi, Vuokko Kinnula, Juha Kere, Pentti Tukiainen, and Tarja Laitinen
We performed a genomewide scan in six multiplex families with familial idiopathic pulmonary fibrosis (IPF) who orig-
inated from southeastern Finland. The majority of the Finnish multiplex families were clustered in the region, and the
population history suggested that the clustering might be explained by an ancestor shared among the patients. The
genomewide scan identified five loci of interest. The hierarchical fine mapping in an extended data set with 24 families
originating from the same geographic region revealed a shared 110 kb to 13 Mb haplotype on chromosome 4q31, which
was significantly more frequent among the patients than in population-based controls (odds ratio 6.3; 95% CI 2.5–15.9;
). The shared haplotype harbored two functionally uncharacterized genes, ELMOD2 and LOC152586, of whichPp .0001
only ELMOD2 was expressed in lung and showed significantly decreased messenger-RNA expression in IPF lung ( )np 6
when compared with that of healthy lung ( ; ). Our results suggest ELMOD2 as a novel candidate gene fornp 7 Pp .05
susceptibility in familial IPF.
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Idiopathic pulmonary fibrosis (IPF [MIM 178500]) is a
chronic, late-onset disease of lung parenchyma with un-
known etiology. IPF has been treated with corticosteroids
and immunosuppressive agents, but the prognosis and the
response to treatment have remained poor,1 and the es-
timated time of survival from the diagnosis is !3 years.2
The genetic component in the development of the dis-
ease is poorly understood, but, since the 1950s, many an-
ecdotal cases of familial IPF (FPF) have been described in
the literature.3–8 According to our nationwide study, FPF
explained 3%–4% of all IPF cases in Finland, which is
slightly more than in the United Kingdom (0.5%–2.2%).6,9
In both countries, the overall prevalence of IPF was at the
same level (in Finland, 16–18 in 100,000).9 Although the
mode of inheritance of FPF is unknown, an autosomal
dominant model with reduced penetrance has been pro-
posed.6,10 The structures of the multiplex families that we
identified in Finland support this hypothesis.9
In Finland, both sporadic and familial cases were found
more frequently in southeastern Finland (Savo Province)
than anywhere else in the country. Of study families, 65%
originated from three rural municipalities where the prev-
alence of FPF was 50-fold higher than in the rest of the
country. On the basis of Finnish population history, we
know that the villages in this area are !50 generations old
and remained relatively isolated until the 20th century.
The isolation resulted in local enrichments of especially
recessive but also dominant mutations that cause late-on-
set diseases.11 The strong clustering led us to hypothesize
that at least some of the patients with IPF may share a
common ancestor. This allowed us to further assume that
the patients share not only the same mutation but also
the same ancestral chromosomal region of up to 10 cM
around the mutation.12,13 In this situation, a genomewide
linkage analysis combined with haplotype association anal-
ysis within the linkage peak should be well able to locate
a susceptibility gene for IPF.
To map the loci linked to IPF, we performed a genome-
wide search in six pedigrees. Five of these pedigrees orig-
inated from the cluster of FPF.9 Three loci with the highest
NPL and two loci with a potential shared haplotype were
studied further with a dense set of markers, and the family
cohort was expanded to 24 families originating from the
same or nearby areas. To test for the best observed hap-
lotype association, the family data set was further ex-
panded to 35 families, including families from across the
country.
For the genomewide search to localize susceptibility
genes, we used patients with IPF whose diagnoses had
been verified according to the American Thoracic Society/
European Respiratory Society diagnostic criteria.9,14 Their
clinical characteristics are shown in table A1 (online only).
For the other family members who were genotyped, the
physician-diagnosed IPF was excluded by an interview (dis-
cussed in detail in the online-only appendix). All partici-
pants signed an informed consent form and donated their
blood samples. The study was approved by the Ethics Com-
mittee of Helsinki University Hospital, Helsinki, and by
the Finnish Ministry of Social Affairs and Health.
In the nationwide epidemiological study of IPF, we iden-
tified 17 multiplex families in Finland.9 In six of those
families, there were two or three affected siblings. All these
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Figure 1. Pedigree structures in the genomewide scan ( pedigrees), fine mapping (Genome scan  Fine mapping;np 6 np 24
pedigrees), and susceptibility-haplotype association study on chromosome 4 (Genome scan  Fine mapping  Replication data set;
pedigrees). Affected family members are indicated by blackened symbols. Individuals who donated their blood sample fornp 35
genotyping are marked with an asterisk (*).
families were included in the genomewide scan without
further selection (fig. 1). Genotyping was performed for
14 patients and their 33 first-degree relatives. Five of the
six pedigrees, traced for 3–5 generations, originated from
the three municipalities in Savo where we previously ob-
served a 50-fold increased risk of FPF compared with the
rest of the country.9 The remaining pedigree originated
150 km west of the geographic cluster of affected popu-
lation. On the basis of genealogy, no links between the
families were found within the last 3–5 generations.
The genomewide scan was performed, with a commer-
cially available microsatellite marker set (Applied Biosys-
tems Linkage Mapping Set MD-10), with an average inter-
val between the markers of 10.6 cM. The genotyping suc-
cess rate was 83%. NPL analysis was performed using GENE-
HUNTER 2.0.15 None of the markers or families showed an
exceptional tendency for Mendelian errors. Three loci (fig.
A1 [online only]) that exceeded NPL 1.5 were localized on
chromosome 3 at marker D3S1278 (NPL 1.7; ; in-Pp .06
formation content 57%), on chromosome 4 at marker
D4S424 (NPL 1.7; ; information 60%), and on chro-Pp .05
mosome 13 at marker D13S265 (NPL 1.6; ; infor-Pp .06
mation 71%).
Genomewide mapping in IPF is challenging for several
reasons. Because of the short life expectancy of the pa-
tients, the enrollment period for recruiting informative
families for linkage analyses is very short. Since IPF is a
late-onset disease, all family members aged !60–70 years
will have uncertain affection status. IPF is a rare disease,
and it is most likely that a portion of familial cases go
unnoticed because of the insufficient or noninformative
pedigree history and changes in clinical practice and di-
agnostics over the years. The small number of the study
pedigrees with limited information for linkage suggested
that it is still possible to miss a true disease locus. There-
fore, we visually inspected the haplotypes reconstructed
by GENEHUNTER in all the chromosomal regions that
showed positive NPL scores and were potentially shared
by the affected individuals within a family and across fam-
ilies. Two chromosomal regions appeared to be of interest.
On chromosomes 9 and 12, several patients shared the
same haplotype, up to 30 cM in length, identified by 1–
4 consecutive markers.
To maximize the information content for linkage and
to detect or exclude a potential haplotype association, we
used the principle of hierarchical genotyping in the ex-
tended family data set (fig. 1, “Genome scan” and “Fine
mapping” panels). Five loci on chromosomes 3, 4, 9, 12,
and 13 were selected for fine mapping. For fine mapping,
we genotyped 63 additional microsatellite markers and
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Figure 2. The shared susceptibility haplotype identified, in 8 of 24 families, within the linkage peak on chromosome 4 (upper panel)
and the genes located within or in the immediate vicinity of the susceptibility haplotype, according to the Genome Browser (lower
panel). The genotyped alleles are shown as positions on genomic clone NT_016606.15. The shared haplotype at its shortest is shown
with dark gray and is shown at its longest with light gray. The marker that showed the best linkage is marked with a circle ().
Multiplex families are marked with an asterisk (*). LOC152586 and the first three exons of ELMOD2 are located within the haplotype
(shown in gray). Short coiled-coil protein (SCOC), calmegin (CLNG [MIM 601858]), and uncoupling protein 1 (UCP1 [MIM 113730]) are
located outside the shared haplotype.
one SNP; the order and average intervals between the
markers were estimated from the Human Genome Se-
quence. All the multiplex families that were not suited for
the linkage analysis were included, as were nuclear fam-
ilies who originated from the same region where the en-
richment of the FPF was detected but in whom we were
not able to confirm the familial background of the disease.
A total of 33 patients and their 60 unaffected family mem-
bers were genotyped. We added a total of 9 markers to
3q13; 28 markers to 4q31, 6 markers to 9q21, 4 markers
to 12p12-q12, and 17 markers to 13q31 (table A2 [on-
line only]). With the added markers, the linkage became
stronger on chromosomes 3 (at D3S1303, NPL 2.07; Pp
; information 83%), chromosome 4 (at D4S1586, NPL.05
2.09; ; information 74%), and chromosome 13 (atPp .02
D13S281, NPL 2.4; ; information 84%), but it weak-Pp .01
ened on chromosome 12 (at D12S310, NPL 0.1; ;Pp .4
information 67%) and on chromosome 9 (at D9S167, NPL
1.0; ; information 79%).Pp .2
We then considered haplotypes shared between patients.
In contrast to any other loci, on chromosome 4, the pa-
tients shared a haplotype in 8 of the 24 families (fig. 2).
The shared haplotype between the families was 110 kb
(fig. 2, dark gray box) at its shortest and was 13 cM (fig.
2, light gray box) at its longest, defined by 4–16 consec-
utive highly informative markers. The susceptibility hap-
lotype, with shared alleles 2*2*6*6*, was delimited, both
upstream and downstream, by two recombinations. In ad-
dition to the weakened linkage results on chromosomes
9 and 12, the putative shared haplotypes were broken
down and the chromosomes excluded. On chromosome
3 with 9 additional markers (marker density, on average,
4.4 cM), no evidence of a shared haplotype between pa-
tients was found, and it was excluded. On chromosome
13, a conserved haplotype among patients was observed,
but the same haplotype was as common among the un-
affected family members so showed no evidence of a dis-
ease association.
We estimated the frequency of susceptibility haplotype
2*2*6*6* with markers 2902739 and 2921606 (named ac-
cording to their positions on genomic clone NT_016606.15
[Entrez Nucleotide]) for alleles 6*6* (fig. 2), which were
always inherited in linkage disequilibrium and were suf-
ficiently informative to tag haplotype 2*2*6*6*. The data
set was expanded, with all the families recognized during
the study as a small replication data set (one affected sib
pair and 10 uniplex families from across Finland). In total,
we genotyped 45 patients from 35 families (13 multiplex
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Figure 3. By in situ hybridizations of human lung-specific mRNA,
expression of ELMOD2 found surrounding the nucleus of alveolar
macrophages (thin arrows) and as perinuclear expression in epithe-
lial cells on the alveolar wall (thick arrows).
and 22 uniplex) (fig. 1). As controls, we used 50 regional
individuals (including the spouses of the probands) and
93 blood donors from across Finland. In 38% (5 of 13) of
multiplex families, the affected family members shared
the susceptibility haplotype (fig. 1, families 6, 17, 18, 34,
and 36). Four of these families originated from the cluster
of three municipalities. Correspondingly, in 27% (7 of 22)
of uniplex families (fig. 1, families 21, 23, 24, 31, 73, 74,
and 77), the proband was a haplotype 2*2*6*6* carrier, and
four of these families originated from the cluster. Among
the control individuals from Savo Province, the hetero-
zygous carriership of the haplotype was 4% (2 of 50)
among controls from the region, and 9.6% (9 of 93)
among the controls from across Finland. The carriership
of the susceptibility haplotype was significantly higher
among the patients (12 of 35) when compared with the
regional controls (2 of 50 individuals; odds ratio [OR] 12.5;
95% CI 2.6–60.6; ) and with the combined poolPp .0004
of controls (11 of 143 individuals; OR 6.3; 95% CI 2.5–
15.9; ).Pp .0001
To fully explore the genetic variation in the associated
110-kb haplotype shared by several families, we sequenced
the nonrepetitive DNA segments in this interval (from
position 2866166 to position 2975765 in NT_016606.15)
in two individuals (an affected father and his daughter),
both heterozygous carriers of the haplotype. The chromat-
ograms were inspected visually by two independent readers,
and sequences were aligned using the Pregap and gap4 soft-
ware from the Staden package. These sequences were com-
pared with NT_016606.15. We observed a total of 37 SNPs
and two small insertion/deletion polymorphisms (table A3
[online only]). Most of the polymorphisms have not been
reported elsewhere.
On the basis of UCSC Genome Bioinformatics, two non-
overlapping genes—ELMOD2 and LOC152586, encoded in
the opposite directions—are located within the shared seg-
ment (fig. 2). None of the polymorphisms, identified by
sequencing the susceptibility haplotype, are located on
the coding regions of either one. The ELMOD2 gene con-
sists of nine exons that encode a 293-aa protein (Entrez-
Gene GeneID 255520).16 Exons 1–3 are located within the
susceptibility haplotype (fig. 2). All nine exons and exon-
intron boundaries of ELMOD2 were sequenced in one
affected patient from each genome-scan family. The se-
quencing revealed no mutations in the coding regions
or exon-intron boundaries. We studied ELMOD2 mRNA
expression using commercially available Human Multiple
Tissue cDNA panels I and II (BD Biosciences) and ampli-
cons spanning exons 2–9, and we observed that ELMOD2
is expressed in all studied tissues and cell types, includ-
ing human lung (fig. A2 [online only]). Also, both (1) the
healthy (CCL-151) and IPF-derived fibroblast (CCL-134)
cell lines (data not shown) and (2) the MTC cDNA panel
(BD Biosciences) representing activated and resting mono-
cyte and lymphocyte cell types expressed ELMOD2 (data
not shown).
The other gene, LOC152586, is poorly characterized (En-
trezGene GeneID 152586). Several overlapping ESTs can
be found at UniGene, most probably encoded by a single
gene. All the identified exons are located within the sus-
ceptibility haplotype. We used the IMAGE:5267198 clone
(IMAGE Consortium) that contained one of the longest
potential ORFs (147 aa) for in vitro translation assay, but
it failed to produce any peptide (fig. A2 [online only]).
With use of Human Multiple Tissue panels I and II cDNA
and amplicons covering 1,143 bp of the cDNA, the expres-
sion was identified only in testis (fig. A2 [online only]).
Using in situ hybridization, we recognized expression
of ELMOD2 in alveolar macrophages and alveolar walls in
healthy lung (fig. 3). In contrast, even after trying several
hybridization conditions, we were not able to detect any
specific signal for ELMOD2 in IPF lung samples (data not
shown). We analyzed ELMOD2 mRNA expression in IPF
lung by RT-PCR on biopsies from six patients with end-
stage IPF and seven healthy control individuals (fig. 4A).
Snap-frozen lung biopsies were taken during surgery, and
all diagnoses were verified by histology with use of the
criteria presented by Katzenstein and Myers.17 Individ-
ual variation occurred among both patients and controls.
However, when relative expression intensities were com-
pared, the ELMOD2 expression level was significantly lower
among the patients than among the controls ( )Pp .05
(fig. 4B), which supports the negative result observed by
in situ hybridization.
We reported elsewhere an unusual clustering of FPF in
three neighboring municipalities of Savo Province in Fin-
land.9 Five of six families informative for linkage originated
from these three municipalities. This gave us a unique pos-
sibility to plan our mapping strategy on the assumption
that several patients of the region, both familial and spo-
radic, descend from the same ancestor who lived 10–40
generations ago, which explains the geographic clustering
of the disease and is similar to several other Mendelian
diseases mapped successfully in Finland.12,13
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Figure 4. A, ELMOD2 mRNA expression studied with use of lung biopsies derived from patients with IPF ( ) and healthy controlnp 6
individuals ( ). B, The mean intensity of mRNA expression, significantly decreased among patients when compared with healthynp 7
controls (mean intensity of ELMOD2/GAPDH mRNA expression [SEM]; the asterisk [*] denotes ).Pp .05
Our genomewide scan identified five potentially inter-
esting regions showing either suggestive linkage or hap-
lotype sharing among the patients. Knowing that the ge-
nome-scan families are most likely not informative enough
to find linkage with genomewide significance, we settled
for suggestive linkage but explored further all the genomic
regions that were potentially shared by the patients. For
the hierarchical fine mapping, we extended the data with
the rest of familial and sporadic cases that we had iden-
tified from Savo Province. Only on chromosome 4q31.1
did we find suggestive linkage (NPL 2.1) and a conserved
haplotype, which varied in size from 110 kb to 13 Mb.
The shared haplotype was present in one-third of the
index families, which was significantly more frequent
than among the regional or population-based controls
(OR 12.5, 95% CI 2.6–60.6, ; and OR 6.3, 95%Pp .0004
CI 2.5–15.9, , respectively). The haplotype wasPp .0001
found in 38% of the multiplex families and in 27% of the
families in which familial background of the disease could
be confirmed. In some of these seemingly sporadic pa-
tients, we could identify the shared haplotype up to 8 Mb,
which suggests that at least a part of uniplex and multiplex
families are related within the past 10–15 generations (fig.
2, families 17 and 21).
We identified several SNPs from the critical region, but
the coding regions of the identified genes were intact
among both the carriers and the noncarriers of the sus-
ceptibility haplotype. Intronic SNPs do not change the
structure of the encoded protein, but they may change
the expression level and splicing of genes.18,19 This has
been reported recently in several gene-mapping stud-
ies.20–22 Although the mapping results obtained in the pres-
ent study were computed in a small family cohort, the
involvement of ELMOD2 as a susceptibility gene for IPF
was further supported by the decreased expression of
ELMOD2 in IPF lung compared with healthy lung. At
present, the biological functions of ELMOD2 in lung are
unknown, and further studies are needed before its direct
involvement in the pathogenesis of IPF can be deter-
mined. ELMOD2 belongs to a protein family that ex-
presses a highly conserved domain found in a number
of eukaryotic proteins, including Ced-12 and ELMO1-3.
These molecules are known to interact in signaling path-
ways involved with apoptosis, phagocytosis, cell engulf-
ment, and cell migration.
Differences in clinical manifestations and histological
findings between FPF and sporadic IPF have not been stud-
ied at large, but the entities are indistinguishable.6,9,23
Therefore, it is plausible to suggest that the signaling path-
ways present in FPF may also be of importance in sporadic
IPF. Our genome scan among the Finnish families suggests
a novel positional candidate. On the basis of altered ex-
pression in IPF lung and the proposed functional prop-
erties, ELMOD2 becomes the prime candidate susceptibil-
ity gene for FPF.
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